<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320303</url>
  </required_header>
  <id_info>
    <org_study_id>2016PhB175-01</org_study_id>
    <nct_id>NCT04320303</nct_id>
  </id_info>
  <brief_title>CMV Infection and Immune Intervention After Transplantation</brief_title>
  <official_title>CMV Infection and Immune Intervention After Haploidentical Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective or even the&#xD;
      only way to cure blood malignant diseases. Cytomegalovirus (CMV) infection is a serious early&#xD;
      complication of allo-HSCT. Its high incidence and poor prognosis can cause a series of&#xD;
      terminal organ diseases such as CMV pneumonia, encephalitis, and enteritis,which seriously&#xD;
      affecting the prognosis of patients post allo-HSCT.&#xD;
&#xD;
      Our data show that rapid reconstruction of NK cells after transplantation can reduce the&#xD;
      incidence of CMV infection. Patients with a rapid reconstruction of NKG2C after&#xD;
      transplantation have a low CMV infection rate, and patients with strong secretion of&#xD;
      IFN-gamma of NK after transplantation have low CMV infection.&#xD;
&#xD;
      Our previous research showed that trophoblast cells transfected with IL-21 and 4-1BBL can&#xD;
      achieve a large number of clinical-grade expansion of NK cells (mIL-21 / 4-1BBL NK cells),&#xD;
      and mIL-21 / 4-1BBL NK cells It is safe to treat patients with minimal residual disease (MRD)&#xD;
      positive AML after transplantation, and can induce MRD to turn negative. Previous studies&#xD;
      have shown that adoptive infusion of expanded NK cells after haplotype transplantation is&#xD;
      safe and can improve the functional reconstruction of NK cells. Therefore, we hypothesized&#xD;
      that the infusion of NK cells can improve the antiviral capacity of NK cells, thereby&#xD;
      effectively reducing the CMV infection. Incidence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of CMV infection post transplantation</measure>
    <time_frame>within 180 days post transplantation</time_frame>
    <description>Whether to reduce the incidence of CMV infection in patients post haploidentical transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of refractory CMV infection post transplantation</measure>
    <time_frame>within 180 days post transplantation</time_frame>
    <description>Whether to reduce the incidence of refractory CMV infection in patients post haploidentical transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of CMV disease post transplantation</measure>
    <time_frame>within 180 days post transplantation</time_frame>
    <description>Whether to reduce the incidence of CMV disease in patients post haploidentical transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enhanced anti-CMV function of reconstituted NK cells</measure>
    <time_frame>within 180 days post transplantation</time_frame>
    <description>Whether to enhance the anti-CMV function of reconstituted NK cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of TRM</measure>
    <time_frame>within 180 days post transplantation</time_frame>
    <description>Whether to reduce the incidence of transplantation related mortality in patients post haploidentical transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of overall survival</measure>
    <time_frame>within 180 days post transplantation</time_frame>
    <description>Whether to increase the incidence of overall survival in patients post haploidentical transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of disease free survival</measure>
    <time_frame>within 180 days post transplantation</time_frame>
    <description>Whether to increase the incidence of disease free survival in patients post haploidentical transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>CMV Viremia</condition>
  <condition>Transplantation Infection</condition>
  <arm_group>
    <arm_group_label>adaptive NK cells infusion post transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptive donors expanded NK cells infusion at day 20±3d and 27±3d post transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>expanded NK cells</intervention_name>
    <description>Donor derived expanded NK cells were infused to patients at around days 20±3d, and 27±3d post transplantation.</description>
    <arm_group_label>adaptive NK cells infusion post transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with acute leukemia (AL) or myelodysplastic syndrome (MDS) or myeloma or&#xD;
             lymphoma undergoing haploidentical allogeneic stem cell transplantation&#xD;
&#xD;
          2. No CMV infection by 20 days ± 3 days after transplantation&#xD;
&#xD;
          3. No active acute GVHD by 20 days ± 3 days after transplantation&#xD;
&#xD;
          4. The dose of prednisolone was less than 0.5mg / kg / d within 72 hours before and after&#xD;
             infusion of NK cells&#xD;
&#xD;
          5. Prior to transplantation, the CMV IgG of the recipient and donor were positive, and&#xD;
             the recipient had a suitable donor to expand NK cells.&#xD;
&#xD;
          6. Patient age 16-65 years&#xD;
&#xD;
          7. Donor age 16-65 years&#xD;
&#xD;
          8. Patient Karnofsky score&gt; 70%&#xD;
&#xD;
          9. Estimated survival&gt; 3 weeks&#xD;
&#xD;
         10. Patient agrees to participate in study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants in any other clinical trials within 1 month before enrollment&#xD;
&#xD;
          2. Active infection&#xD;
&#xD;
          3. HBV or HCV or HIV carriers&#xD;
&#xD;
          4. With moderate to severe renal dysfunction (blood creatinine&gt; 130umol / L) and / or&#xD;
             liver dysfunction (total bilirubin&gt; 34umol / L, ALT, AST&gt; 2 times the upper limit of&#xD;
             normal) before NK infusion&#xD;
&#xD;
          5. Researchers do not consider it appropriate to participate in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiang-Yu Zhao</last_name>
    <phone>861088325949</phone>
    <email>zhao_xy@bjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Institute of Hematology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang-Yu Zhao, M.D., PhD</last_name>
      <phone>+861088325949</phone>
      <email>zhao_xy@bjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2020</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojun Huang,MD</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Viremia</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

